Contineum Therapeutics, Inc.
CTNM
Analytical Summary
Contineum Therapeutics, Inc. shows mixed fundamentals. Consider comparing against peers in the Healthcare sector before making investment decisions.
4-Year Financial Trajectory
AnnualHealth Breakdown
Statement lens
Choose the reporting cadence, isolate a period range, or search directly for a metric.
| Metric | FY 2025 Dec 31, 2025 10-K ↗ | FY 2024 Dec 31, 2024 10-K ↗ | FY 2023 Dec 31, 2023 10-K ↗ | FY 2022 Dec 31, 2022 10-K ↗ |
|---|---|---|---|---|
| EPS Growth YoY (%) |
0.5%
Caution
Caution
Year-over-year change in earnings per share
Optimal:
> 10%
|
N/M | — | — |
| Net Income Growth YoY (%) |
-41.9%
Weak
Weak
Year-over-year change in net income |
N/M | — | — |
| FCF Growth YoY (%) |
-16.3%
Weak
Weak
Year-over-year change in free cash flow |
N/M | — | — |
| Metric | FY 2025 Dec 31, 2025 10-K ↗ | FY 2024 Dec 31, 2024 10-K ↗ | FY 2023 Dec 31, 2023 10-K ↗ | FY 2022 Dec 31, 2022 10-K ↗ |
|---|---|---|---|---|
| Operating Margin (%) (%) | — | — |
32.2%
Excellent
Excellent
Operating income as a percentage of revenue
Optimal:
> 15%
vs Sector:
Above avg (+114%)
|
— |
| Effective Tax Rate (%) (%) |
0.0%
Excellent
↓
Excellent
Declining
Actual taxes paid relative to pre-tax income
Optimal:
15-25%
|
0.0%
Excellent
Excellent
Actual taxes paid relative to pre-tax income
Optimal:
15-25%
|
1.9%
Excellent
Excellent
Actual taxes paid relative to pre-tax income
Optimal:
15-25%
|
— |
| Profit Margin (%) (%) | — | — |
45.4%
Excellent
Excellent
Net income as a percentage of revenue
Optimal:
> 15%
vs Sector:
Above avg (+279%)
|
— |
| FCF Margin (%) (%) | — | — |
37.9%
Excellent
Excellent
Free cash flow as a percentage of revenue
Optimal:
> 10%
|
— |
| FCF / Net Income (x) |
0.93x
Caution
↑
Caution
Improving
Free cash flow relative to reported net income
Optimal:
> 1x
|
0.79x
Caution
Caution
Free cash flow relative to reported net income
Optimal:
> 1x
|
0.83x
Caution
Caution
Free cash flow relative to reported net income
Optimal:
> 1x
|
— |
| Metric | FY 2025 Dec 31, 2025 10-K ↗ | FY 2024 Dec 31, 2024 10-K ↗ | FY 2023 Dec 31, 2023 10-K ↗ | FY 2022 Dec 31, 2022 10-K ↗ |
|---|---|---|---|---|
| Return on Invested Capital (%) |
-26.1%
Weak
↓
Weak
Declining
Return earned on debt + equity capital invested
Optimal:
> 10%
|
-25.7%
Weak
Weak
Return earned on debt + equity capital invested
Optimal:
> 10%
|
-23.2%
Weak
Weak
Return earned on debt + equity capital invested
Optimal:
> 10%
|
— |
| Return on Capital (%) (%) |
-24.6%
Weak
↓
Weak
Declining
Operating profit relative to total assets
Optimal:
> 10%
|
-23.9%
Weak
Weak
Operating profit relative to total assets
Optimal:
> 10%
|
12.3%
Good
Good
Operating profit relative to total assets
Optimal:
> 10%
|
— |
| Return on Common Equity (%) (%) |
-23.0%
Weak
↑
Weak
Improving
Profit generated per dollar of shareholder equity
Optimal:
> 15%
vs Sector:
Below avg (-253%)
|
-21.3%
Weak
Weak
Profit generated per dollar of shareholder equity
Optimal:
> 15%
vs Sector:
Below avg (-242%)
|
-33.4%
Weak
Weak
Profit generated per dollar of shareholder equity
Optimal:
> 15%
vs Sector:
Below avg (-323%)
|
— |
| Metric | FY 2025 Dec 31, 2025 10-K ↗ | FY 2024 Dec 31, 2024 10-K ↗ | FY 2023 Dec 31, 2023 10-K ↗ | FY 2022 Dec 31, 2022 10-K ↗ |
|---|---|---|---|---|
| Sales/Revenue/Turnover (USD) | — | $0.00 | $50.00M | — |
| Depreciation Expense (USD) | $323.00K | $258.00K | $195.00K | — |
| Net Income, GAAP (USD) | $-59.98M | $-42.26M | $22.72M | — |
| Operating Cash Flow (USD) | $-55.31M | $-32.84M | $19.35M | — |
Secondary lens
Benchmark Lens
Compare CTNM against peers after checking the statement evidence.
Open lens
Benchmark Lens
Compare CTNM against peers after checking the statement evidence.
Percentile Rankings
How CTNM compares to all companies
Peer Comparison
CTNM vs similar peers
Compare CTNM with peers
Stack CTNM against similar companies across every metric on this page.
north_east Open comparisonbar_chart Data from SEC EDGAR XBRL filings
Synced yesterday 4 years · 15 quarters